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Laparoscopic pancreatoduodenectomy (LPD) in pancreatic cancer is primarily criticized for its technical 
and oncological safety. Although solid evidence has not yet been established, many institutions are 
performing LPD for pancreatic cancer patients, with continuous efforts to ensure oncologic safety. In this 
video, we demonstrated a case of standard LPD combined with vascular resection in pancreatic cancer.
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INTRODUCTION
Laparoscopic pancreatoduodenectomy (LPD) remains a contro-
versial treatment method for pancreatic ductal adenocarcinoma, 
as laparoscopic resection followed by reconstruction of the re-
sected bile duct and pancreatic remnants should be performed. 
In pancreatic head cancers, laparoscopic resection of the pan-
creaticoduodenal unit could be quite difficult due to potential 
tumor invasion near the major vascular structures. Moreover, it 
involves a risk of postoperative complications, such as pancre-
atitis and cholangitis. Therefore, it is difficult to ensure patient 
safety and the completion of the procedure [1].
However, the recent National Comprehensive Cancer Network 
guidelines recommend minimally invasive surgical treatment, 
such as laparotomy, for resectable pancreatic cancer. However, 
only level 3 evidence is currently available regarding LPD for 
pancreatic head cancers. No prospective randomized control trial 
(RCT) has compared LPD and open pancreatoduodenectomy 
(PD) in terms of the short-term and long-term oncologic out-
comes for pancreatic cancer because of the following reasons: (1) 
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LPD for pancreatic cancer is technically difficult, (2) only a few 
qualified surgeons are available, and (3) a very small proportion 
of patients with pancreatic cancer are eligible for this interven-
tion. 
In this article, a surgical approach to LPD for pancreatic head 
cancer was described, and recent updates on short-term onco-
logic outcomes were brief ly summarized.
MATERIALS AND METHODS
We previously described our surgical LPD technique for peri-
ampullary tumors [2,3]. In this section, additional oncologic 
concepts are introduced to develop a surgical strategy for LPD. 
Finally, our institutional experiences with LPD for pancreatic 
head cancer are presented. The relevant video clip is provided 
with this article (Supplementary Video 1).
Extent of surgery 
Several important prospective RCTs have determined the opti-
mal extent of surgical resection for pancreatic cancer [4]. Stan-
dard PD was not considered inferior and had comparable onco-
logic outcomes to LPD in treating resectable pancreatic cancers. 
Hence, LPD with standard dissection is considered technically 
available, feasible, and safe for well-selected pancreatic head can-
cers. 
Superior mesenteric artery lateral margin 
The pancreatic neck margins, retroperitoneal margins, and supe-
rior mesenteric artery (SMA) lateral margin should be carefully 
obtained during PD, as pancreatic cancer cells, regardless of loca-
tion, can invade and infiltrate pancreatic nerve tissues leading to 
the major arteries—the SMA, common hepatic artery, and celiac 
axis [5]. Recently, we reported the potential application of indo-
cyanine green (ICG) to secure the SMA lateral margin during 
LPD. ICG (5 mg/2 cm3) was prepared and intravenously injected 
when dissecting uncinate process of the pancreas [6].
Combined vascular resection 
PD combined with venous resection (VR) is no longer contrain-
dicated for pancreatic head cancer. However, patients who under-
went PD-VR exhibited higher rates of complications, including 
in-hospital and 30-day mortality [7]. Therefore, LPD-VR needs to 
be performed by experienced surgeons in eligible patients. Vari-
ous techniques of VR (tangential vs. segmental) and reconstruc-
tion (end-to-end vs. inter-position graft) have been reported, but 
not concluded which one is superior on perioperative outcome 
[8]. Despite demonstrating the safety and feasibility of LPD with 
combined resection of the superior mesenteric-splenic-portal 
venous conf luence in treating pancreatic cancer, we acknowledge 
the difficulty in performing this technique. Therefore, we prefer 
venous tangential resection to segmental resection in LPD for 
pancreatic cancer to enhance patient safety (Fig. 1). 
RESULTS
General characteristics of patients 
From June 2014 to November 2020, the medical records of 50 
patients, of which 44 underwent LPD and six underwent robot-
assisted LPD for pancreatic head cancer were collected and 
reviewed. The clinical characteristics of the patients are summa-
rized in Table 1.
Perioperative outcomes 
The perioperative outcomes are summarized in Table 2. The 
mean operation time was 483.7 ± 68.7 minutes and the mean 
Fig. 1. Laparoscopic view after resection of pancreatic head cancer. (A) Segmental resection of the portal vein (PV) and end-to-end anastomosis, anas-
tomosis site (white arrows). (B) Tangential resection of the PV, stump of resection (white arrows). BD, bile duct; SMA, superior mesenteric artery; CHA, 
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estimated blood loss was 419.4 ± 461.5 mL. The mean pancreatic 
duct size was 4.6 ± 3.1 mm. Among the patients, nine (18.0%) 
underwent LPD-VR, 20 (40.0%) had a soft pancreas, and two pa-
tients (4.0%) developed a postoperative pancreatic fistula. 
Short-term oncologic outcomes 
Table 3 shows the pathological characteristics. In the overall 
cohort, the mean tumor and lymph node sizes were 2.5 ± 1.0 cm 
and 15.1 ± 9.5 cm, respectively. Among the patients, 44 (88.0%) 
had R0 status, five (10.0%) underwent R1 resection, and one (2.0%) 
underwent R2 resection.
DISCUSSION
LPD for pancreatic head cancer has theoretical advantages. First, 
a minimally invasive surgery can enhance postoperative recov-
ery, thereby preserving the patient’s functional capacity and ini-
tiating adjuvant chemotherapy promptly. Second, LPD has fre-
quently reduced intraoperative bleeding, thus lowering the risk 
of an intraoperative transfusion, which is known to adversely 
impact patient survival [9].
Although margin-negative radical pancreatectomy is most 
effective in treating pancreatic cancer, more than 80% of pan-
creatic cancer patients have unresectable tumors at the time of 
diagnosis. However, considering future advancements facilitat-
ing early diagnosis, the number of stage I and stage II patients, 
having tumors confined to the pancreas, is expected to increase. 
Therefore, the oncologic role of LPD should be reevaluated be-
cause most patients with stage I and II pancreatic cancer could 
undergo LPD using the described surgical strategy.
We have previously reviewed the potential feasibility of LPD 
for pancreatic head cancer [10]. We found that LPD can provide 
equivalent or superior short-term oncologic outcomes and com-
parable long-term survival outcomes to those of the standard 
procedure, suggesting its technical feasibility and oncologic 
safety as a treatment method [3]. Although RCTs are regarded 
as the highest level of evidence, other circumstances should 
be considered. We therefore acknowledge some skepticism on 
whether RCTs can serve as the fundamental basis in choosing 
the appropriate treatment for patients. This is true for complex 
treatment modalities, such as LPD. Therefore, despite the ret-
rospective study design, previous experiences and decisions of 
expert surgeons on treating their patients should still be con-
sidered. However, a successful RCT could be useful in choosing 
an appropriate surgical approach for pancreatic cancer patients. 
Table 1. General characteristics of patients
Characteristic MIPD
No. of patients 50
Sex, male/female 21 (42.0)/29 (58.0)
Age (yr) 66.3 ± 8.8
Preoperative BMI (kg/m2) 23.4 ± 2.5
ASA PS classification
   I 2 (4.0)
   II 17 (34.0)
   III 31 (62.0)
Preoperative CA 19-9 (U/mL) 227.4 ± 435.4
Neoadjuvant CCRT 7 (14.0)
Data are expressed as number only, mean ± standard deviation, or num-
ber (%).
MIPD, minimally invasive pancreatoduodenectomy; BMI, body mass in-
dex; ASA, American Society of Anesthesiologists; PS, physical status; CA 
19-9, carbohydrate antigen 19-9; CCRT, concurrent chemoradiotherapy.
Table 2. Perioperative outcomes
Characteristic MIPD (n = 50)
Operation time (min) 483.7 ± 68.7
Estimated blood loss (mL) 419.4 ± 461.5
Intraoperative transfusion 2 (4.0)
Pancreas texture
   Soft 20 (40.0)
   Hard 28 (56.0)
Pancreas duct size (mm) 4.6 ± 3.1
POPF grade
   None 34 (68.0)
   Biochemical leak 14 (28.0)
   B 1 (2.0)
   C 1 (2.0)
DGE grade
   None 45 (90.0)
   A 4 (8.0)
   B 0 (0)
   C 1 (2.0)
Postoperative hemorrhage 0 (0)
Vascular resection 9 (18.0)
Open conversion 4 (8.0)
Adjuvant chemotherapy 34 (68.0)
Hospital stay (day) 22.5 ± 18.6
Data are expressed as mean ± standard deviation or number (%).
MIPD, minimally invasive pancreatoduodenectomy; POPF, postoperative 
pancreatic fistula; DGE, delayed gastric emptying.
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Thus, we recommend a more careful clinical investigation into 
the potential application of LPD in pancreatic cancers.
NOTES
Ethical statements
The study was conducted in compliance with the principles of 
the Declaration of Helsinki and the study protocol was reviewed 
and approved by Institutional Review Board (IRB) of Yonsei Uni-
versity College of Medicine (registered on July 16, 2019; registra-
tion number: 2019-1411-001). A waiver of informed consent was 
approved by the IRB. 
Authors’ contributions
Conceptualization: CMK
Visualization: WJL, HKH, SHK, SYR
Writing–original draft: MC
Writing–review & editing: WJL, HKH, SHK, SYR, CMK
All authors read and approved the final manuscript.
Conflict of interest





Seoung Yoon Rho, https://orcid.org/0000-0002-1265-826X
Sung Hyun Kim, https://orcid.org/0000-0001-7683-9687
Ho Kyoung Hwang, https://orcid.org/0000-0003-4064-7776
Woo Jung Lee, https://orcid.org/0000-0001-9273-261X
Chang Moo Kang, https://orcid.org/0000-0002-5382-4658 
Supplementary materials 
Supplementary materials can be found via https://doi.org/10.7602/
jmis.2021.24.3.169.
REFERENCES
1. Kang CM, Lee SH, Chung MJ, Hwang HK, Lee WJ. Laparoscopic 
pancreatic reconstruction technique following laparoscopic pancre-
aticoduodenectomy. J Hepatobiliary Pancreat Sci 2015;22:202-210. 
2. Navarro JG, Kang CM. Pitfalls for laparoscopic pancreaticoduode-
nectomy: Need for a stepwise approach. Ann Gastroenterol Surg 
2019;3:254-268. 
3. Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. Comparing lapa-
roscopic and open pancreaticoduodenectomy in patients with pan-
creatic head cancer: oncologic outcomes and inflammatory scores. J 
Hepatobiliary Pancreat Sci 2020;27:124-131. 
4. Wang W, He Y, Wu L, Ye L, Yao L, Tang Z. Efficacy of extended 
versus standard lymphadenectomy in pancreatoduodenectomy for 
pancreatic head adenocarcinoma. An update meta-analysis. Pancre-
atology 2019;19:1074-1080. 
5. Yi SQ, Miwa K, Ohta T, et al. Innervation of the pancreas from the 
perspective of perineural invasion of pancreatic cancer. Pancreas 
2003;27:225-229. 
6. Rho SY, Kim JS, Chong JU, et al. Indocyanine green perfusion 
imaging-guided laparoscopic pancreaticoduodenectomy: potential 
application in retroperitoneal margin dissection. J Gastrointest Surg 
2018;22:1470-1474.
7. Peng L, Zhou Z, Cao Z, Wu W, Xiao W, Cao J. Long-term oncologi-
cal outcomes in laparoscopic versus open pancreaticoduodenectomy 
for pancreatic cancer: a systematic review and meta-analysis. J Lapa-
roendosc Adv Surg Tech A 2019;29:759-769. 
8. Kendrick ML, Sclabas GM. Major venous resection during total lapa-
Table 3. Short-term oncologic outcome
Variable MIPD
Tumor size (cm) 2.5 ± 1.0
T stage 44
   T1 13 (29.5)
   T2 27 (61.4)
   T3 4 (9.1)
N stage 45
   N0 24 (53.3)
   N1 14 (31.1)
   N2 7 (15.6)
Retrieved LN (cm) 15.1 ± 9.5
Positive LN (cm) 1.4 ± 2.3
Invasion 49
   Lymphovascular 20 (40.8)
   Perineural 42 (85.7)
R status 50
   0 44 (88.0)
   1 5 (10.0)
   2 1 (2.0)
Data are expressed as mean ± standard deviation, number only, or num-
ber (%).
MIPD, minimally invasive pancreatoduodenectomy; LN, lymph node. 
Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma
www.e-jmis.org
173
roscopic pancreaticoduodenectomy. HPB (Oxford) 2011;13:454-458. 
9. Kim SY, Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. Intraoper-
ative transfusion is independently associated with a worse prognosis 
in resected pancreatic cancer-a retrospective cohort analysis. J Clin 
Med 2020;9:689.
10. Kang CM, Lee WJ. Is laparoscopic pancreaticoduodenectomy feasible 
for pancreatic ductal adenocarcinoma? Cancers (Basel) 2020;12:3430.
